Trump says experimental drugs may have saved him from virus

WASHINGTON (AP) — President Donald Trump said Friday he could have become very ill and might not have recovered from COVID-19 without experimental drugs, a far worse outlook than what his doctors were telling the American people.

“I was asking the doctors today … and I said, ‘How bad was I?’ They said: ‘You could have been very bad. You were going into a very bad phase,'” Trump told Rush Limbaugh during his radio show.

“It looked like it was going to be a big deal and you know what that means, right? That means bad because I’ve lost five people,” Trump added, referring to acquaintances who have died.

Trump said that after contracting the virus, he was “not in the greatest of shape.” He added that “I might not have recovered at all” without treatment with experimental drugs.

Trump’s comments on the seriousness of his case of coronavirus contrast

Read More

Allergy Rhinitis Drugs Market – Actionable Research on COVID-19 | Growing Awareness about Allergic Rhinitis to Boost the Market Growth

The global allergy rhinitis drugs market size is poised to grow by USD 2.4 billion during 2020-2024, progressing at a CAGR of almost 4% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis

This press release features multimedia. View the full release here:

Technavio has announced its latest market research report titled Global Allergy Rhinitis Drugs Market 2020-2024 (Graphic: Business Wire)

This growing awareness about allergic rhinitis has proved critical in helping patients get treated in the early stages of the disease. It also increases the chances of accurate diagnosis by physicians. Globally, the prevalence of allergic rhinitis has

Read More

Pfizer, BioNTech, Regeneron Hit With Patent Lawsuits Over COVID-19 Drugs And Vaccines

Three top names in the fight against the coronavirus and the COVID-19 disease that can result from it have been sued for patent infringement. The trio includes Regeneron Pharmaceuticals (NASDAQ:REGN), Pfizer (NYSE:PFE), and BioNTech (NASDAQ:BNTX). The plaintiff is privately held Allele Biotechnology and Pharmaceuticals.

Allele alleges that the three all used its mNeonGreen fluorescent protein to develop their COVID-19 products without paying royalties for the substance. Medical researchers inject fluorescent proteins into cells to track reactions within those bodies. This tracking is used to help determine the effect of medicines and vaccines on the body.

Regeneron is currently developing REGN-COV2, an experimental cocktail of two antibodies to treat COVID-19. The company became a hot topic last week when it was revealed President Donald Trump was administered REGN-COV2 as part of his treatment for COVID-19.

Pfizer and BioNTech have teamed up to develop a coronavirus vaccine; their candidate, BNT162b2, is considered

Read More

Some Health Workers Suffering From Addiction Steal Drugs Meant For Patients : NPR

The federal government estimates one in 10 healthcare workers experience substance use disorder. There is rising concern that medical professionals are stealing powerful opioid pain medications meant for their patients.

Kaz Fantone/NPR

hide caption

toggle caption

Kaz Fantone/NPR

The federal government estimates one in 10 healthcare workers experience substance use disorder. There is rising concern that medical professionals are stealing powerful opioid pain medications meant for their patients.

Kaz Fantone/NPR

When Kristin Waite-Labott, a nurse in Wisconsin, began stealing fentanyl and morphine from her hospital’s medical supply cabinets, she found it was relatively easy to cover her tracks.

Her drug inventory paperwork often didn’t add up, but she found coworkers willing to cover for her.

“They trusted me” she said. “Unfortunately I was taking advantage of that trust and that happens all the time.”

But Waite-Labott’s addiction to fentanyl quickly spiraled out of control.

“Taking it one time, I instantly

Read More

Increased Risk of Severe COVID With Anti-B-Cell MS Drugs?

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

Concerns are being raised over an increased risk of severe COVID-19 outcomes in multiple sclerosis (MS) patients on anti-CD20 B-cell depleting drugs such as ocrelizumab and rituximab following presentation of new data.

A Global Data Sharing Initiative study, including information on more than 1500 MS patients, most of whom had suspected or confirmed COVID-19, has shown increased risks of hospital admission, treatment in the intensive care unit (ICU), and ventilation for patients on ocrelizumab and rituximab compared with other MS drugs.

The study was presented at a special session on multiple sclerosis and COVID-19 at a final “Encore” event on September 26 as part of the 8th Joint European Committee for Treatment and Research in Multiple Sclerosis-Americas Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS) 2020, this year known as MSVirtual2020.

This adds to an

Read More

Global Acne Drugs Markets 2020-2025 with Profiles of Allergan, Bausch Health, Galderma, GlaxoSmithKline, and Pfizer

The MarketWatch News Department was not involved in the creation of this content.

Dublin, Sep 29, 2020 (GLOBE NEWSWIRE via COMTEX) —
The “Acne Drugs: Global Markets” report has been added to’s offering.

This report offers a detailed picture of the acne drug market. It highlights the current and future market potential for acne drugs and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, and trends in the market. The report also covers market projections through 2025 as well as key market players.

This report details market shares for acne drugs based on drug type, route of administration, distribution channel, and geography. Based on drug type, the market is segmented into the retinoid, antibiotics, hormonal agent, and other segments. Based on the route of administration, the market is segmented into topical and oral. Based on the distribution channel, the market segmented into prescription-based and

Read More

Unapproved drugs found in cognitive supplements: study

Five unapproved drugs were found in over-the-counter supplements advertising better cognitive function, according to a recent study.

The study’s authors said the drugs’ presence “suggest serious risks to consumers and weaknesses in the regulatory framework under which supplements are permitted to be introduced in the U.S.”

Findings were published Wednesday in the peer-reviewed journal, Neurology Clinical Practice.

Dr. Pieter Cohen, associate professor at Harvard Medical School, and his team searched through two supplement databases, National Institute of Health’s Dietary Supplement Label Database and the Natural Medicines Database, for products containing drugs not authorized for human use in the U.S.

Five unapproved drugs were found in over-the-counter supplements advertising better cognitive function, per a recent study. (iStock)

Five unapproved drugs were found in over-the-counter supplements advertising better cognitive function, per a recent study. (iStock)


In all, 10 supplements were tested, which resulted in the detection of five unapproved drugs: omberacetam, aniracetam, vinpocetine, phenibut and picamilon.

Read More

Trump Approves Final Plan to Import Drugs From Canada

President Donald Trump, outlining his “America First Health Plan” on Thursday, announced that his administration will allow the importation of prescription drugs from Canada.

The final plan clears the way for Florida and other states to implement a program bringing medications across the border, despite the strong objections of drugmakers and the Canadian government.

But it does not allow states to import biologic drugs, including insulin.

Florida, the biggest swing state in the presidential election, is one of six states to pass laws seeking federal approval to import drugs. Trump’s announcement came the same day counties in Florida began sending out vote-by-mail ballots.

Florida Gov. Ron DeSantis, a close ally of the president’s, is a strong advocate of importing drugs. His administration has already advertised for a contractor to run the state program and is expected to announce Tuesday which companies have bid for the three-year, $30 million state contract.

Read More

HHS Issues Rule for Importation of Prescription Drugs

“We believe this proposed rule is a potentially effective tool to implement the laws that several states have now enacted to make certain drugs more affordable,” David Certner, AARP’s legislative counsel and legislative policy director for government affairs, said in a March letter to Food and Drug Administration (FDA) Commissioner Stephen Hahn, M.D. Certner’s letter commenting on the proposed rule called on the Trump administration to make other proposals “to help lower drug prices and ensure access to needed medications.” In addition, the letter strongly urged the federal government “to continue working with Congress towards the enactment of meaningful prescription drug legislation that will lower drug prices and out-of-pocket costs.”

The final regulation will allow specific drugs to be imported, as long as they meet federal standards for safety and saving money. Though the rule goes into effect in 60 days, HHS officials could not say when actual importation plans

Read More

FDA adds abuse warning to labels for drugs like Xanax, Valium

Reacting to an upsurge in abuse of benzodiazepine sedatives such as Valium, Xanax and Ativan, U.S. officials on Wednesday added a “Boxed Warning” to the drugs’ labels, cautioning about the danger.

Benzodiazepines are tranquilizers commonly prescribed to help ease issues such as anxiety, seizures, insomnia and panic disorders.

But “while benzodiazepines are important therapies for many Americans, they are also commonly abused and misused, often together with opioid pain relievers and other medicines, alcohol and illicit drugs,” U.S. Food and Drug Agency Commissioner Dr Stephen Hahn said in an agency news release.

So he said the FDA is now “taking measures and requiring new labeling information to help health care professionals and patients better understand that while benzodiazepines have many treatment benefits, they also carry with them an increased risk of abuse, misuse, addiction and dependence.”

Illicit use of “benzos” has been on the rise, and the drugs are often

Read More